Harfouche Cyril J, Brucker Michael J, Pacella Salvatore J
Aesthet Surg J Open Forum. 2024 Aug 20;6:ojae068. doi: 10.1093/asjof/ojae068. eCollection 2024.
Tissue reinforcement techniques with porcine acellular dermal matrices (ADMs) have been widely adopted as standard care in treating capsular contracture. However, the application of alternative xenograft or mesh materials has not been widely studied.
To examine the efficacy of OviTex PRS Reinforced Tissue Matrix (Resorbable) (TELA Bio, Malvern, PA), a hybrid ovine-reinforced mesh, in comparison with STRATTICE Reconstructive Tissue Matrix (Allergan, Irvine, CA), in patients with advanced capsular contracture.
A retrospective review was conducted on patients who underwent breast revision surgery for Baker Grade III or IV capsular contracture. Patient data were reviewed for outcomes, complications, cost, and postoperative incidence of recurrent capsular contracture after treatment with each specific mesh.
Fifty-nine of 89 breasts (66.3%) were treated with OviTex and 30 (33.7%) were treated with STRATTICE. All patients experienced a reduction in Baker grades. In patients treated with OviTex, 96.6% ( = 57) of breasts had a postoperative Baker Grade I with the remaining 3.4% ( = 2) breasts presenting with a Baker Grade II. In comparison, 73.3% ( = 22), 23.3% ( = 7), and 3.3% ( = 1) of the STRATTICE cohort presented with Baker Grades I, II, and III, respectively. This demonstrated a statistically significant improvement in Baker grade capsular contracture in the OviTex cohort ( < .05) compared with STRATTICE. Average cost was $27.37/cm for STRATTICE compared with $22.28/cm for OviTex PRS.
OviTex may be successfully utilized to treat capsular contracture. Patient outcomes may be superior to STRATTICE in recurrent capsular contracture, particularly when a previous ADM had been utilized. Cost data show improved savings with the use of OviTex compared with STRATTICE.
使用猪脱细胞真皮基质（ADM）的组织强化技术已被广泛用作治疗包膜挛缩的标准治疗方法。然而，替代异种移植物或网状材料的应用尚未得到广泛研究。
比较OviTex PRS强化组织基质（可吸收）（TELA Bio，马尔文，宾夕法尼亚州），一种混合羊膜强化网片，与STRATTICE重建组织基质（艾尔建，尔湾，加利福尼亚州），在晚期包膜挛缩患者中的疗效。
对接受贝克III级或IV级包膜挛缩乳房修复手术的患者进行回顾性研究。回顾患者数据，了解每种特定网片治疗后的结果、并发症、成本和复发性包膜挛缩的术后发生率。
89例乳房中有59例（66.3%）接受了OviTex治疗，30例（33.7%）接受了STRATTICE治疗。所有患者的贝克分级均有所降低。在接受OviTex治疗的患者中，96.6%（n = 57）的乳房术后为贝克I级，其余3.4%（n = 2）的乳房为贝克II级。相比之下，STRATTICE组分别有73.3%（n = 22）、23.3%（n = 7）和3.3%（n = 1）的患者为贝克I级、II级和III级。这表明与STRATTICE相比，OviTex组在贝克级包膜挛缩方面有统计学上的显著改善（P <.05）。STRATTICE的平均成本为27.37美元/平方厘米，而OviTex PRS为22.28美元/平方厘米。
OviTex可成功用于治疗包膜挛缩。在复发性包膜挛缩方面，患者的治疗效果可能优于STRATTICE，尤其是在先前已使用ADM的情况下。成本数据显示，与STRATTICE相比，使用OviTex可节省更多费用。
